We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
Read MoreHide Full Article
Shares of Novavax (NVAX - Free Report) were down 19.6% on April 10 after the United States Health and Human Services (“HHS”) Secretary Robert F. Kennedy Jr., a well-known vaccine skeptic, raised concerns regarding the efficacy of the company’s protein-based COVID-19 vaccine.
In a recent interview with CBS News, the HHS Secretary raised concerns about NVAX’s COVID-19 vaccine. He stated that it employs a single-antigen approach and mentioned that it has never worked for such respiratory diseases. The HHS Secretary also said that they are now shifting the focus toward vaccines that offer a multiple-antigen approach.
NVAX Seeking Full Approval for COVID-19 Jab
NVAX’s COVID-19 vaccine has been authorized for emergency use in the United States since 2022. The vaccine is also approved/authorized for use in multiple markets like Australia, Canada, Europe, India and Indonesia.
However, NVAX has filed a biologics license application (BLA) seeking full approval of the vaccine. A decision from the FDA was expected earlier this month.
The market is speculating that the resignation of a key FDA official, Dr. Peter Marks, has been the reason for the delay in FDA’s decision on NVAX’s vaccine. Dr. Marks resigned citing irreconcilable differences with the new HHS Secretary last week.
Novavax has not received an official response from the FDA related to the status of the BLA.
The BLA was based on data from a phase III study, which showed the vaccine was safe and effective for the prevention of COVID-19.
Year to date, shares of Novavax have plunged 32.5% compared with the industry’s decline of 7.9%.
Image Source: Zacks Investment Research
Other Stocks That Declined
The concerns raised by the HHS Secretary in the latest interview also affected other vaccine makers in the United States. Pfizer (PFE - Free Report) was down 3.9%, while Moderna (MRNA - Free Report) was down 8.1% after the markets closed on Thursday.
While Novavax uses a protein-based COVID-19 vaccine, PFE and MRNA market mRNA-based COVID-19 vaccines, namely Comirnaty and Spikevax, respectively.
Kennedy Rules Out Personnel Change for Delay in NVAX Jab Approval
In the interview with CBS News, Robert F. Kennedy Jr. ruled out possible personnel changes when asked about the delay in the FDA approval of NVAX’s COVID-19 vaccine.
Notably, in his resignation letter posted by the New York Times, Dr. Marks had called out the newly appointed HHS Secretary for promoting “misinformation and lies” about the safety of FDA-approved vaccines. Several stocks in the vaccine and gene therapy space tumbled on the news.
Dr. Marks expressed strong concerns about efforts to undermine vaccine safety. He warned about the rising hesitancy toward vaccines and their consequences, citing the recent measles outbreak as an example of what happens when trust in vaccines is eroded.
Some Wall Street analysts worry that his absence could weaken the FDA’s role in ensuring timely access to safe and effective therapies, potentially adding to the challenges already facing the biotech sector.
Image: Shutterstock
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
Shares of Novavax (NVAX - Free Report) were down 19.6% on April 10 after the United States Health and Human Services (“HHS”) Secretary Robert F. Kennedy Jr., a well-known vaccine skeptic, raised concerns regarding the efficacy of the company’s protein-based COVID-19 vaccine.
In a recent interview with CBS News, the HHS Secretary raised concerns about NVAX’s COVID-19 vaccine. He stated that it employs a single-antigen approach and mentioned that it has never worked for such respiratory diseases. The HHS Secretary also said that they are now shifting the focus toward vaccines that offer a multiple-antigen approach.
NVAX Seeking Full Approval for COVID-19 Jab
NVAX’s COVID-19 vaccine has been authorized for emergency use in the United States since 2022. The vaccine is also approved/authorized for use in multiple markets like Australia, Canada, Europe, India and Indonesia.
However, NVAX has filed a biologics license application (BLA) seeking full approval of the vaccine. A decision from the FDA was expected earlier this month.
The market is speculating that the resignation of a key FDA official, Dr. Peter Marks, has been the reason for the delay in FDA’s decision on NVAX’s vaccine. Dr. Marks resigned citing irreconcilable differences with the new HHS Secretary last week.
Novavax has not received an official response from the FDA related to the status of the BLA.
The BLA was based on data from a phase III study, which showed the vaccine was safe and effective for the prevention of COVID-19.
Year to date, shares of Novavax have plunged 32.5% compared with the industry’s decline of 7.9%.
Image Source: Zacks Investment Research
Other Stocks That Declined
The concerns raised by the HHS Secretary in the latest interview also affected other vaccine makers in the United States. Pfizer (PFE - Free Report) was down 3.9%, while Moderna (MRNA - Free Report) was down 8.1% after the markets closed on Thursday.
While Novavax uses a protein-based COVID-19 vaccine, PFE and MRNA market mRNA-based COVID-19 vaccines, namely Comirnaty and Spikevax, respectively.
Kennedy Rules Out Personnel Change for Delay in NVAX Jab Approval
In the interview with CBS News, Robert F. Kennedy Jr. ruled out possible personnel changes when asked about the delay in the FDA approval of NVAX’s COVID-19 vaccine.
Notably, in his resignation letter posted by the New York Times, Dr. Marks had called out the newly appointed HHS Secretary for promoting “misinformation and lies” about the safety of FDA-approved vaccines. Several stocks in the vaccine and gene therapy space tumbled on the news.
Dr. Marks expressed strong concerns about efforts to undermine vaccine safety. He warned about the rising hesitancy toward vaccines and their consequences, citing the recent measles outbreak as an example of what happens when trust in vaccines is eroded.
Some Wall Street analysts worry that his absence could weaken the FDA’s role in ensuring timely access to safe and effective therapies, potentially adding to the challenges already facing the biotech sector.
Novavax, Inc. Price
Novavax, Inc. price | Novavax, Inc. Quote
NVAX's Zacks Rank
Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.